This page shows the latest basal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.
It included women with either cervical squamous cell carcinoma or adenocarcinoma, who were randomised to receive Libtayo monotherapy or an investigator’s choice of commonly used chemotherapy. ... The NSCLC authorisation closely followed another
This is the second approval for Libtayo this month, with the immunotherapy previously winning an authorisation in previously-treated advanced basal cell carcinoma. ... As a latecomer to the immunotherapy class, Libtayo first entered the market in 2018
cell carcinoma and cervical cancer. ... Sanofi and Regeneron aren’t holding back on the scale of their research programme, and these include trials in squamous cell carcinoma of the head and neck, melanoma, colorectal cancer, prostate
The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... metastatic non-small cell lung cancer (NSCLC),
The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... after basal cell carcinoma (BCC) and the deadliest
The data in cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer, comes from a single-arm, open-label trial involving 82 patients and showed an overall ... The company plans to have pivotal trials ongoing in first-line
More from news
Approximately 5 fully matching, plus 15 partially matching documents found.
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The small-molecule drug blocks part of the Sonic hedgehog
295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Abzena's technology is used to humanise and de-immunise antibodies by avoiding CD4+ T-cell epitopes.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...